68Ga-DOTATOC PET/CT

DRUG5 trials

Sponsors

Sue O'Dorisio, British Columbia Cancer Agency, Central Hospital, Nancy, France

Conditions

CarcinoidCarcinoid TumorCarcinoid TumorsGanglioneuromaGastrinomaGlucagonomaInfective EndocarditisInsulinoma

Phase 1

Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors

CompletedNCT01619865

Sue O'DorisioCarcinoid Tumors, Medulloblastoma, Neuroblastoma +1

Start: 2012-02-21End: 2017-08-27Updated: 2021-07-27

Phase 2

Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors

CompletedNCT02441062

Sue O'DorisioCarcinoid Tumors, Medulloblastoma, Neuroblastoma +1

Start: 2015-09-30End: 2020-01-20Updated: 2020-12-21

Early Feasibility Study of Somatostatin Receptors PET Imaging for the Diagnosis of Infective Endocarditis

CompletedNCT05183555

Central Hospital, Nancy, FranceInfective Endocarditis

Start: 2022-05-16End: 2024-06-18Updated: 2024-09-26

Unknown Phase

DOTATOC PET/CT for Imaging NET Patients

Active, not recruitingNCT03583528

British Columbia Cancer AgencyCarcinoid, Ganglioneuroma, Gastrinoma +13

Start: 2018-07-11End: 2028-09-30Target: 800Updated: 2026-05-12

Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging

British Columbia Cancer AgencyCarcinoid Tumor, Neuroblastoma, Neuroendocrine Tumors +3

Start: 2019-11-01End: 2024-08-01Target: 60Updated: 2021-01-26